Metagenomi, Inc. (NASDAQ:MGX) Short Interest Update

Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 2,640,000 shares, a growth of 21.7% from the January 15th total of 2,170,000 shares. Based on an average trading volume of 2,300,000 shares, the short-interest ratio is presently 1.1 days. Approximately 14.1% of the company's stock are sold short.

Institutional Investors Weigh In On Metagenomi

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its position in shares of Metagenomi by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company's stock valued at $28,000 after buying an additional 7,256 shares during the period. Verition Fund Management LLC acquired a new stake in shares of Metagenomi in the 3rd quarter valued at about $82,000. Jacobs Levy Equity Management Inc. raised its stake in Metagenomi by 209.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company's stock valued at $296,000 after acquiring an additional 92,468 shares during the last quarter. Geode Capital Management LLC lifted its position in Metagenomi by 105.8% in the third quarter. Geode Capital Management LLC now owns 338,031 shares of the company's stock valued at $734,000 after purchasing an additional 173,796 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Metagenomi during the 3rd quarter valued at approximately $33,000.

Analyst Ratings Changes

MGX has been the topic of several analyst reports. HC Wainwright boosted their target price on Metagenomi from $7.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, December 10th. Chardan Capital restated a "buy" rating and issued a $15.00 price target on shares of Metagenomi in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $16.67.

Metagenomi Trading Up 7.6 %

Shares of NASDAQ:MGX traded up $0.18 on Wednesday, reaching $2.56. The company had a trading volume of 951,215 shares, compared to its average volume of 1,394,394. The firm's 50 day simple moving average is $3.06 and its 200-day simple moving average is $2.66. Metagenomi has a 52-week low of $1.61 and a 52-week high of $12.50.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.